From regulatory flexibility to reimbursement changes, how Canadian regulators and payers are managing the COVID-19 crisis
Canadian regulators and payers across the country have been actively taking steps to manage the evolving COVID-19 crisis. In this article, we highlight some of the key regulatory changes and guidance put in place by both the federal and provincial regulators as well as payers, which spans the gamut from regulatory pathway developments to clinical trials to pharmacy scope of practice to reimbursement issues.
To read the full article, please see the attached PDF.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.